CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia

Background of the KEYLYNK-007 trial for advanced solid tumours

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma